Human immunodeficiency virus infections in pregnancy

International Journal of Gynecology and Obstetrics

Volumn 57, Issue 1, 1997, Pages 73-80

  Minkoff, H L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREAST FEEDING; FEMALE; GYNECOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; NONHUMAN; OBSTETRICS; PATIENT COUNSELING; PERINATAL INFECTION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION;

EID: 0030928192     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(97)85610-X     Document Type: Review

References (32)

1. Centers for Disease Control and Prevention. First 500,000 AIDS cases - United States, 1995. MMWR 1995;44:849-853 (Level III)
2. National Center for Health Statistics. Annual summary of births, marriages, divorces, and deaths: United States, 1994. Monthly vital statistics report; vol 43, no. 13. Hyattsville, Maryland: Department of Health and Human Services, Public Health Service (Level II-2)
3. Davis SF, Byers RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995; 274:952-955 (Level III)
4. Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995;44(RR-7):1-15 (Level III)
5. National Research Council. State of the epidemic. In: AIDS: the second decade. Washington, DC: National Academy Press, 1990:38-80 (Level III)
6. Centers for Disease Control. AIDS in women - United States. MMWR 1990;39:845-846 (Level III)
7. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43(RR-11):1-20 (Level III)
8. Maury W, Potts BJ, Rabson AB. HIV-1 infection of first-trimester and term human placental tissue: a possible mode of maternal-fetal transmission. J Infect Dis 1989;160:583-588 (Level II-2)
9. Centers for Disease Control. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR 1987;36:509-515 (Level III)
10. Ranki A, Valle S-L, Krohn M, Antonen J, Allain J-P, Leuther M, et al. Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet 1987;2:589-593 (Level II-2)
11. American Fertility Society. New guidelines for the use of semen donor insemination: 1990. Fertil Steril 1990;53(suppl 1):1S-13S (Level III)
12. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996;334:1617-1623 (Level II-3)
13. Minkoff H, Burns DN, Landesman S, Youchah J, Goedert JJ, Nugent RP, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995;173: 585-589 (Level II-2)
14. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected thresh-old for mother-to-child transmission. Proc Natl Acad Sci USA 1995;92:12100-12104 (Level II-3)
15. Dickover RE, Garratty EM, Herman SA, Sim M, Plaeger S, Boyer P, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996; 275:599-605 (Level II-2)
16. Landesman SH, Burns D. Quantifying HIV. JAMA 1996; 275:640-641 (Level III)
17. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180 (Level I)
18. Bulterys M, Chao A, Muneyemana S, Kurawige J-B, Nawrocki P, Habimana P, et al. Maternal human immunodeficiency virus 1 infection and intrauterine growth: a prospective cohort study in Butare, Rwanda. Pediatr Infect Dis J 1994;13:94-100 (Levei II-2)
19. Temmerman M, Chomba EN, Ndinya-Achola J, Plummer FA, Coppens M, Piot P. Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol 1994;83:495-501 (Level II-2)
20. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:46-55 (Level III)
21. Sperling RS, Stratton P, and the members of the obstetric-gynecologic working group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Treatment options for human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1992;79: 443-448 (Level III)
22. Sobel JD. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 1986;315:1455-1458 (Level I)
23. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR 1993;42 (RR-14):75-81 (Level III)
24. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-154 (Level III)
25. Toltzis P, Mourton T, Magnuson T. Effect of zidovudine on preimplantation murine embryos. Antimicrob Agents Chemother 1993;37:1610-1613 (Level I)
26. Pizzo PA, Butler KM. In the vertical transmission of HIV, timing may be everything. N Engl J Med 1991;325:652-654 (Level III)
27. Van de Perre P, Simonon A, Msellati P, Hitimana D-G, Vaira D, Bazubagira A, et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to infant. A prospective cohort study in Kigali, Rwanda. N Engl J Med 1991;325:593-598 (Level II-2)
28. Centers for Disease Control. Public health service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(RR-1):1-14 (Level III)
29. Gerberding JL, Littell C, Tarkington A, Brown A, Schecter WP. Risk of exposure of surgical personnel to patients' blood during surgery at San Francisco General Hospital. N Engl J Med 1990;322:1788-1793 (Level III)
30. Centers for Disease Control and Prevention. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-472 (Level III)
31. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-935 (Level II-2)
32. American Medical Association. Council on Ethical and Judicial Affairs. Ethical issues involved in the growing AIDS crisis. JAMA 1988;259:1360-1361 (Level III)